Ivabradine and the SIGNIFY conundrum

Simple item page
dc.contributor.authorBeltrame, J.F.
dc.date.issued2015
dc.descriptionEditorial
dc.description.abstractThis editorial refers to ‘Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: the SIGNIFY study’, by K.M. Fox et al., on page doi:10.1093/eurheartj/XXX Stable angina is a prevalent and disabling condition that occurs in 10–14% of those aged 65–84 years,1 with population studies suggesting that almost a third of affected patients experience an angina episode at least once a week.2 Treatment focuses upon the alleviation of angina symptoms and the prevention of cardiac events. Although the development of cardioprotective agents has received considerable attention in recent years, there has been less progress with novel antianginal agents.
dc.description.statementofresponsibilityJohn F. Beltrame
dc.identifier.citationEuropean Heart Journal, 2015; 36(46):3297-3299
dc.identifier.doi10.1093/eurheartj/ehv368
dc.identifier.issn0195-668X
dc.identifier.issn1522-9645
dc.identifier.orcidBeltrame, J.F. [0000-0002-4294-6510]
dc.identifier.urihttp://hdl.handle.net/2440/94558
dc.language.isoen
dc.publisherOxford University Press
dc.rights© The Author 2015. For permissions please email: journals.permissions@oup.com
dc.source.urihttps://doi.org/10.1093/eurheartj/ehv368
dc.subjectHumans
dc.subjectHeart Rate
dc.subjectCoronary Artery Disease
dc.titleIvabradine and the SIGNIFY conundrum
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications